Lipocine Inc. announced that Health Canada has approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with hypogonadism. The approval was granted to licensing partner Verity Pharmaceuticals, which holds exclusive commercial rights to the product in North America and plans to launch it in the Canadian market by the end of 2026. TLANDO offers an oral alternative to existing injections and topical gels, featuring a fixed dosing regimen that does not require dose titration. Lipocine Inc. is a biopharmaceutical company developing oral therapeutics using its proprietary drug-delivery technology platform.
